EP2560484A4 - PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES - Google Patents

PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES

Info

Publication number
EP2560484A4
EP2560484A4 EP11772343.7A EP11772343A EP2560484A4 EP 2560484 A4 EP2560484 A4 EP 2560484A4 EP 11772343 A EP11772343 A EP 11772343A EP 2560484 A4 EP2560484 A4 EP 2560484A4
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11772343.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2560484A1 (en
Inventor
Hosheng Tu
Hsing-Wen Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NANOMEGA MEDICAL Corp
Original Assignee
NANOMEGA MEDICAL CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/799,283 external-priority patent/US7910086B1/en
Priority claimed from US12/800,848 external-priority patent/US7879313B1/en
Application filed by NANOMEGA MEDICAL CORP filed Critical NANOMEGA MEDICAL CORP
Publication of EP2560484A1 publication Critical patent/EP2560484A1/en
Publication of EP2560484A4 publication Critical patent/EP2560484A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11772343.7A 2010-04-21 2011-01-31 PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES Withdrawn EP2560484A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/799,283 US7910086B1 (en) 2005-01-04 2010-04-21 Nanoparticles for protein drug delivery
US12/800,848 US7879313B1 (en) 2005-01-04 2010-05-24 Nanoparticles for protein drug delivery
PCT/US2011/000183 WO2011133198A1 (en) 2010-04-21 2011-01-31 A pharmaceutical composition of nanoparticles

Publications (2)

Publication Number Publication Date
EP2560484A1 EP2560484A1 (en) 2013-02-27
EP2560484A4 true EP2560484A4 (en) 2014-05-28

Family

ID=44834439

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11772343.7A Withdrawn EP2560484A4 (en) 2010-04-21 2011-01-31 PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES

Country Status (8)

Country Link
EP (1) EP2560484A4 (ja)
JP (1) JP2013525351A (ja)
KR (1) KR20130100897A (ja)
CN (1) CN102970864A (ja)
AU (1) AU2011243226A1 (ja)
CA (1) CA2796853A1 (ja)
RU (1) RU2012144776A (ja)
WO (1) WO2011133198A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014011123A (es) * 2012-03-22 2014-12-05 Nanotherapeutics Inc Composiciones y metodos de administracion oral de particulas de dietilentriaminopentaacetato encapsuladas.
US20140296173A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Llc. Stable nanocomposition comprising epirubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN104740647A (zh) * 2015-04-08 2015-07-01 东莞市麦亘生物科技有限公司 一种艾塞那肽口服制剂及其制备方法
CA2983337A1 (en) * 2015-05-01 2016-11-10 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
GB201507760D0 (en) * 2015-05-06 2015-06-17 Anabio Technologies Ltd Gelated microparticle suitable for oral delivery of therapeutic peptides to the lower intestine
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
JP6850546B2 (ja) * 2016-04-07 2021-03-31 アリメント工業株式会社 極小ソフトカプセルの製造方法
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
KR102083481B1 (ko) * 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
KR102140185B1 (ko) * 2018-09-21 2020-08-03 (주)세포활성연구소 천연물 유래 발효추출물 발모제를 포함하는 하이드로젤 나노입자, 이의 제조방법
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
CN110327221A (zh) * 2019-04-16 2019-10-15 中国人民解放军第四军医大学 一种牙本质胶原纤维脱矿材料及其制备方法与应用
EP4210680A1 (en) 2020-09-07 2023-07-19 Cyprumed GmbH Improved pharmaceutical formulations of glp-1 receptor agonists
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155374A1 (en) * 2005-01-04 2009-06-18 Hsing-Wen Sung Nanoparticles for protein drug delivery
US20090202628A1 (en) * 2005-01-04 2009-08-13 Hsing-Wen Sung Nanoparticles for protein drug delivery
WO2009137711A1 (en) * 2008-05-07 2009-11-12 Medivas, Llc Biodegradable metal-chelating polymers and vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105175A (zh) * 2008-05-27 2011-06-22 香港中文大学 纳米颗粒、制备纳米颗粒和使用纳米颗粒进行细胞标记的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155374A1 (en) * 2005-01-04 2009-06-18 Hsing-Wen Sung Nanoparticles for protein drug delivery
US20090202628A1 (en) * 2005-01-04 2009-08-13 Hsing-Wen Sung Nanoparticles for protein drug delivery
WO2009137711A1 (en) * 2008-05-07 2009-11-12 Medivas, Llc Biodegradable metal-chelating polymers and vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "complexone - definition of complexone by the Free Online Dictionary, Thesaurus and Encyclopedia.", 14 April 2014 (2014-04-14), XP055114484, Retrieved from the Internet <URL:http://www.thefreedictionary.com/complexone> [retrieved on 20140417] *
See also references of WO2011133198A1 *

Also Published As

Publication number Publication date
JP2013525351A (ja) 2013-06-20
RU2012144776A (ru) 2014-05-27
KR20130100897A (ko) 2013-09-12
CA2796853A1 (en) 2011-10-27
AU2011243226A1 (en) 2012-10-11
EP2560484A1 (en) 2013-02-27
CN102970864A (zh) 2013-03-13
WO2011133198A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
EP2560484A4 (en) PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES
ZA201300458B (en) C-met-modulator pharmaceutical compositions
IL225457A0 (en) Pharmaceutical composition
ME02575B (me) Farmaceutska kompozicija
SI2616076T1 (sl) Farmacevtski sestavki
ZA201300718B (en) Pharmaceutical compositions
ZA201207670B (en) Pharmaceutical compositions
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
ZA201304633B (en) A pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
EP2637655A4 (en) PHARMACEUTICAL COMPOSITION OF TAXOIDES
SG10201508982TA (en) Pharmaceutical compositions
GB201001911D0 (en) Pharmaceutical composition
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
ZA201201003B (en) A pharmaceutical composition
ZA201303732B (en) Pharmaceutical compositions
GB201019775D0 (en) Pharmaceutical composition
GB201008590D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140429

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 25/08 20060101AFI20140423BHEP

Ipc: A61K 47/48 20060101ALI20140423BHEP

Ipc: A61K 9/51 20060101ALI20140423BHEP

Ipc: A61K 9/19 20060101ALI20140423BHEP

Ipc: B82Y 5/00 20110101ALI20140423BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140801